A Study to Evaluate the Effect of IV ACHN-490 Injection on the QT/QTc Interval in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the study drug, ACHN-490 Injection, affects the QT interval in normal volunteers. The hypothesis is that the drug will not cause an increase in the QT interval.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

NCT02217930

Qt Interval, Variation in

COMPLETED PHASE1

Phase 1 Study for Safety of ACHN-490

NCT00822978

Healthy

COMPLETED PHASE1

A Study of Soticlestat in Healthy Adults To Evaluate the Effect on QTc Interval

NCT05309902

Healthy Volunteers

WITHDRAWN PHASE1

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

NCT03554304

QT/QTc Interval in Healthy Volunteers

COMPLETED PHASE1

Electrophysiological Effects of a Single 10 μg Dose of Exenatide on the 12-Lead Electrocardiogram QT Interval in Healthy Subjects

NCT00672399

Healthy Subjects

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cardiac Effects in Normal Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Supratherapeutic Dose

20mg/kg ACHN-490 Injection

Group Type EXPERIMENTAL

ACHN-490 Injection

Intervention Type DRUG

20mg/kg IV 30 minute infusion given once

Possible Therapeutic Dose

15mg/kg ACHN-490 Injection

Group Type EXPERIMENTAL

ACHN-490 Injection

Intervention Type DRUG

15mg/kg IV 30 minute infusion given once

Moxifloxacin

400mg moxifloxacin

Group Type ACTIVE_COMPARATOR

Moxifloxacin

Intervention Type DRUG

400mg oral pill given once

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo oral pill given once

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ACHN-490 Injection

20mg/kg IV 30 minute infusion given once

Intervention Type DRUG

ACHN-490 Injection

15mg/kg IV 30 minute infusion given once

Intervention Type DRUG

Moxifloxacin

400mg oral pill given once

Intervention Type DRUG

Placebo

Placebo oral pill given once

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male and female subjects between 18 and 50 years of age and with a body mass index ≥ 18 to ≤ 33 kg/m2, and weight of ≥ 40 to ≤ 100 kg inclusive.
2. Subject is in good health as judged by the investigator based on the laboratory criteria and no clinically significant findings on the medical history or physical examination.
3. Females of child-bearing potential (defined as less than one year post-menopause) are eligible for enrollment if they are not breast feeding, they have a negative serum pregnancy test before study entry, and they are using a highly effective method of contraception for at least 3 months before study drug administration, during the study, and for at least 6 months after study completion.
4. Subjects who are willing to comply with all study activities and procedures and have provided written informed consent prior to any study procedures and have signed and dated a Health Insurance Portability and Accountability Act (HIPAA) authorization form.

Exclusion Criteria

1. A history of additional risk factors for TdP.
2. Unstable cardiovascular disease, including recent myocardial infarction or cardiac arrhythmia.
3. Sustained supine systolic blood pressure \>150 mmHg, or \<110 mmHg in Part 1 or \<100mmHg in Part 2, or a diastolic blood pressure \>95 mmHg at screening or baseline.
4. A resting pulse rate at rest, taken during screening, of \<40 bpm or \>100 bpm.
5. An abnormal screening ECG indicating a second- or third-degree atrioventricular (AV) block, or one or more of the following: QRS \>110 milliseconds (msec), QTcB \>470 msec for females or 450 msec for males, PR interval \>240 msec, or any rhythm other than sinus rhythm, which is interpreted by the Investigator to be clinically significant.
6. Uncontrolled hypertension, asthma, unstable diabetes (type I or type II), thyroid disease, seizures, myasthenia gravis, or any other neuromuscular disorder.
7. Positive results at screening for hepatitis B virus, hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection.
8. History of central nervous system disorders, epilepsy or known seizure disorder (excluding a history of childhood febrile seizures).
9. The subject has a history of any cancer, except basal cell or stage 1 squamous cell carcinoma of the skin, which has not been in remission for at least 5 years prior to the first dose of study drug.
10. Subjects who have any condition possibly affecting drug absorption.
11. History of significant hearing loss or a family history of hearing loss, excluding age related (≥ age 65) hearing loss. A prior diagnosis of sensorineural hearing loss or Ménière's disease.
12. Clinically significant illness, including viral syndromes within 3 weeks of dosing.
13. The use of concomitant medications that prolong the QT/QTc interval.
14. Used prescription medications, over-the-counter (OTC) medications, investigational medications/therapy, vitamins, or nicotine-containing products (eg, cigarettes, cigars, chewing tobacco, snuff, etc.) within 28 days or 5 half-lives, whichever is longer, before dosing of ACHN-490 Injection.
15. Used aminoglycosides within 6 months prior to IMP administration.
16. Used herbal preparations including St. John's wort, ginseng, kava kava, ginkgo biloba, melatonin, and other nutraceuticals within 28 days prior to IMP administration.
17. Consumed caffeine- or xanthine-containing products (eg, tea, coffee, chocolate, cola, etc.), Seville oranges (sour), grapefruit, grapefruit juice, or fish liver oils within 72 hours prior to IMP administration.
18. Current participation in a clinical study of an investigational product.
19. Consumed more than 28 units of ethanol per week at any time in the 6 months before dosing (1 unit of ethanol is equivalent to 8 ounces of beer, 4 ounces of wine, or 1 ounce of spirits) or history of alcoholism and/or drug/chemical abuse. Also, consumption of any amount of ethanol within 72 hours of ACHN-490 Injection dosing.
20. Donated blood or blood components within 60 days prior to receiving study drug.
21. Women who are pregnant (or planning to become pregnant within the next 3 months) or currently breastfeeding.
22. Previous participation in this or any other ACHN-490 Injection study.
23. Known hypersensitivity to aminoglycosides or any component of the ACHN-490 Injection.
24. Subjects with poor venous access.
25. Unable to understand verbal or written English or any other language for which a certified translation of the informed consent is not available.
26. Any other medical, psychological, or social condition which, in the opinion of the PI or the medical monitor, would prevent the subject from fully participating in the study would represent a concern for study compliance or would constitute a safety concern to the subject.
27. An employee of the investigator or study center with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as a family member of the employee or investigator.
28. \* (Part 1 only) \* Acceptable and reproducible spirometry measurements defined as: forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) \< 80% of predicted or FEV1/FVC ratio \<70% of predicted. See Appendix 7 for definitions of acceptability and reproducibility.
29. \* (Part 2 only) \* Known hypersensitivity to moxifloxacin or other quinolones.
30. \* (Part 2 only) \* Taken antacids, sucralfate, multivitamins, or other products with multivalent cations within 8 hours before oral dose in Part 2 or need to take any of the above within 4 hours after the dose administration.
31. \* (Part 2 only) \* Taken warfarin or Class IA or Class III antiarrhythmics within one week prior to study drug administration or expected to need to take any of the above during the study period.
32. \* (Part 2 only) \* Participation in Part 1 of the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes